An imbalance between Smad and MAPK pathways is responsible for TGF-β tumor promoting effects in high-grade gliomas

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 499-507

  Nickl Jockschat, T ^b   Arslan, F ^a,c   Doerfelt, A ^a   Bogdahn, U ^a   Bosserhoff, A ^a   Hau, Peter ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

High grade glioma; MAPK pathway; Smad pathway; TGF

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; OLIGONUCLEOTIDE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; METABOLISM; PHOSPHORYLATION; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 34047270254     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Moses HL, Branum EL, Proper JA and Robinson RA: Transforming growth factor production by chemically transformed cells. Cancer Res 41: 2841-2848, 1981.
2. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2: 442-454, 2002.
3. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M and Weller M: Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by bcl-2 and Transforming Growth Factor-β2. J Neurosci 21: 3360-3368, 2001.
4. Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W and Heffner RRJ: Correlation of endothelin-1 and transforming growth factor beta-1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 56: 435-439, 1997.
5. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J and Weller M: TGF-β1 and TGF-β2 promote glioma cell migration cia up-regulation of alphaVbeta3 integrin expression. Biochem Biophys Res Commun 269: 607-611, 2000.
6. Kjellman C, Olofsson SP, Hansson O, et al: Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89: 251-258, 2000.
7. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W and Schlingensiepen KH: Transforming growth factor-beta mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65: 332-337, 1996.
8. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG and Gold LI: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856, 1993.
9. Von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I and Johnk C: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7: S925-S932, 2001.
10. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S and Cohen A: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4: 549-554, 1995.
11. Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, Tepetes K, Kalogeropoulou C, Tsota I, Kourelis T, Makatsoris T, Karavias D, Scopa CD, Bonikos DS, Kalofonos HP and Petsas T: The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol 180: 201-208, 2004.
12. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y and Matsuzawa Y: High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110: 375-382, 1996.
13. Platten M, Wick W and Weller M: Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis and immune escape. Microsc Res Tech 52: 401-410, 2001.
14. Massagué J: TGF-β signal transduction. Annu Rev Biochem 67: 753-791, 1998.
15. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425: 577-584, 2003.
16. Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20: 133-143, 2001.
17. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J and Massagué J: The TGF-β receptor activation process: an inhibitor- to substratebinding switch. Mol Cell 8: 671-682, 2001.
18. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S and Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17: 3091-3100, 1998.
19. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT and Wang XF: Tumor suppressor Smad4 is a transforming growth factor β-inducible DNA binding protein. Mol Cell Biol 17: 7019-7028, 1997.
20. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B and Kern SE: Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1: 611-617, 1998.
21. Jennings MT and Pietenpol JA: The role of transforming growth factor beta in glioma progression. J Neurooncol 36: 123-140, 1998.
22. Rich J, Borton A, Wang X, Platten M, Wick W and Weller M: Transforming growth factor-beta signaling in cancer. Microsc Res Tech 52: 363-373, 2001.
23. Tchernitsa O, Sers C, Zuber J, Hinzmann B, Grips M, Schramme A, Lund P, Schwende A, Rosenthal A and Schäfer A: Transcriptome profiling in KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 23: 4536-4555, 2004.
24. Schwachtgen JL, Houston P, Campbell C, Sukhatme V and Braddock M: Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. J Clin Invest 101: 2540-2549, 1998.
25. Spandidos DA and Kerr IB: Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br J Cancer 49: 681-688, 1998.
26. Bos JL, Verlaan-De Vries M, Jansen AM, Veeneman GH, van Boom JH and van der Eb AJ: Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res 12: 9155-9163, 1984.
27. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA and Jacks T: Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116, 2001.
28. Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 11: S44-S51, 2001.
29. Kretzschmar M, Doody J, Timokhina I and Massague J: A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 13: 804-816, 1999.
30. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, Hill CS, Beug H and Downward J: Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 14: 2610-2622, 2000.
31. Shen ZJ, Kim SK, Kwon OS, Lee YS and Moon BJ: Specific inhibition of transforming growth factor-beta2 expression in human osteoblast cells by antisense phosphorothioate oligonucleotides. Eur J Biochem 268: 2331-2337, 2001.
32. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J and Martin R: Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49: 5358-5363, 1989.
33. Fanton CP, McMahon M and Pieper RO: Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem 276: 18871-18877, 2001.
34. Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, Bird D and Marshall CJ: ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9: 33-44, 2006.
35. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M and Fontana A: Differential expression of transforming growth factor-β, -β2, snd -β3 by glioblastoma cells, astrocytes and microglia. J Immunol 148: 1404, 1992.
36. INK4B induction and growth inhibition in astrocytes is Smad3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 274: 35053-35058, 1998.
37. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS and Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86: 3474-3478, 1989.
38. Gertwitz AM, Stein CA and Glazer PM: Facilitating oligonucleotides delivery: helping antisense to deliver on its promise. Proc Natl Acad Sci USA 93: 3161-3163, 1996.
39. Warzocha K and Wotowiec D: Antisense strategy: biological utility and prospects in the treatment of hematological malignancies. Leuk Lymphoma 82: 83-90, 1997.
40. Fennewald SM and Rando RF: Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. J Biol Chem 270: 21718-21721, 1995.
41. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkison JL and Stein CA: Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem 270: 2620-2627, 1995.
42. Rockwell P, O'Connor WJ, King K, Goldstein NI, Zhang LM and Stein CA: Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 94: 6523-6528, 1997.
43. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M and Böttinger EP: A mechanism of suppression of TGF-β/Smad-signaling by NF-kappaB/RelA. Genes Dev 14: 187-197, 2000.
44. Saha D, Datta PK and Beauchamp RD: Oncogenic Ras represses Transforming Growth Factor-β/Smad signaling by degrading tumor suppressor Smad 4. J Biol Chem 276: 29531-29537, 2001.
45. Lo RS and Massagué J: Ubiquitin-dependent degradation of TGF-β-activated Smad2. Nat Cell Biol 1: 472-478, 1999.
46. Shi Y and Massagué J: Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113: 685-700, 2003.
47. Tsuda T, Marinetti MR, Masuelli L and Cutler ML: The Ras suppressor RSU-1 localizes to 10p13 and its expression in the U251 glioblastoma cell line correlates with a decrease in growth rate and tumorigenic potential. Oncogene 11: 397-403, 1995.
48. Tsurushima H, Tsuboi K, Yoshii Y, Ohno T, Meguro K and Nose T: Expression of N-ras gene in gliomas. Neurol Med Chir 36: 704-708, 1996.
49. Dasgupta B, Li W, Perry A and Gutmann DH: Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 65: 236-245, 2005.
50. Massagué J, Blain SW and Lo RS: TGF-β signaling in growth control, cancer and heritable disorders. Cell 103: 395-409, 2000.
51. Calonge MJ and Massague J: Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 274: 33637-33643, 1999.
52. Oft M, Peli J, Rudaz C, Schwarz H, Beug H and Reichmann E: TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477, 1996.
53. Kunnimalaiyaan M and Chen H: The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17: 139-142, 2006.
54. Joneson T, Fulton JA, Volle DJ, Chaika OV, Bar-Sagi D and Lewis RE: Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated (ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras effectors. J Biol Chem 273: 7743-7748, 1998.
55. Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351: 289-305, 2000.
56. Besson A, Davy A, Robbins SM and Yong VW: Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene 20: 7398-7407, 2001.
57. Grobben B, Claes P, van Kolen K, Roymans D, Fransen P, Sys SU and Slegers H: Agonists of the P2Y(AC)-receptor activate MAP kinase by a ras-independent pathway in rat C6 glioma. J Neurochem 78: 1325-1338, 2001.
58. Lind CR, Gray CW, Pearson AG, Cameron RE, O'Carroll SJ, Narayan PJ, Lim J and Dragunow M: The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells. Neuroscience 141: 1925-1933, 2006.
59. Coumailleau F, Das V, Alcover A, Raposo G, Vandormael-Pournin S, Le Bras S, Baldacci P, Dautry-Varsat A, Babinet C and Cohen-Tannoudji M: Over-expression of Rififylin, a new RING finger and FYVE-like domain-containing protein, inhibits recycling from the endocytic recycling compartment. Mol Biol Cell 15: 4444-4456, 2004.
60. Tibbetts MD, Shiozaki EN, Gu L, McDonald ER III, El-Deiry WS and Shi Y: Crystal structure of a FYVE-type zinc finger domain from the caspase regulator CARP2. Structure 12: 2257-2263, 2004.
61. Kotaja N, Karvonen U, Janne OA and Palvimo JJ: PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 22: 5222-5234, 2002.
62. Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, Roche PC and Spelsberg TC: Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Breast Cancer Res Treat 86: 75-88, 2004.
63. Ostendorff HP, Bossenz M, Mincheva A, Copeland NG, Gilbert DJ, Jenkins NA, Lichter P and Bach I: Functional characterization of the gene encoding RLIM, the corepressor of LIM homeodomain factors. Genomics 69: 120-130, 2000.
64. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT and Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 83: 456-464, 2000.
65. Liang H, Guo W and Nagarajan L: Chromosomal mapping and genomic organization of an evolutionarily conserved zinc finger gene ZNF277. Genomics 66: 226-228, 2000.
66. Bartee E, Mansouri M, Hovey Nerenberg BT, Gouveia K and Fruh K: Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol 78: 1109-1120, 2004.
67. Ota T, Suzuki Y, Nishikawa T, Otsuki T, et al: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 36: 40-45, 2004.
68. Zenker M, Mayerle J, Lerch MM, Tagariello A, Zerres K, Durie PR, Beier M, Hulskamp G, Guzman C, Rehder H, Beemer FA, Hamel B, Vanlieferinghen P, Gershoni-Baruch R, Vieira MW, Dumic M, Auslender R, Gil-da-Silva-Lopes VL, Steinlicht S, Rauh M, Shalev SA, Thiel C, Ekici AB, Winterpacht A, Kwon YT, Varshavsky A and Reis A: Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome). Nat Genet 37: 1345-1350, 2005.
69. Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, Bannon AW, Boyle WJ, Lacey DL and Han HQ: Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res 64: 8193-8198, 2005.
70. Ohira M, Ootsuyama A, Suzuki E, Ichikawa H, Seki N, Nagase T, Nomura N and Ohki M: Identification of a novel human gene containing the tetratricopeptide repeat domain from the Down syndrome region of chromosome 21. DNA Res 3: 9-16, 1996.
71. Hastie CJ, Carnegie GK, Morrice N and Cohen PT: A novel 50 kDa protein forms complexes with protein phosphatase 4 and is located at centrosomal microtubule organizing centres. Biochem J 3: 845-855, 2000.
72. MacDonald DH, Lahiri D, Sampath A, Chase A, Sohal J and Cross NC: Cloning and characterization of RNF6, a novel RING finger gene mapping to 13q12. Genomics 58: 94-97, 1999.